[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
ZHANG Jian, FANG Huihua.
Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
|
[3] |
WANG Xiang, SUN Shuai, WANG Xinguo, NIU Liying.
Quantitative transfer relationships of Rubia yunnanensis Diels formula granules based on standard decoctions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 891-898.
|
[4] |
LI Ning, JIANG Xiaoya, ZHANG Zezhao, GAO Le, WANG Xinguo, LIU Xiaoming.
Preparation and quality evaluation of standard decoctions of Rosa chinensis Jacq.
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 397-402.
|
[5] |
LIU Bo, GUO Yunxiao, ZHANG Tong, HUANG Lu, HE Lanying, FAN Huihong.
A national reference standard for fructosazine and deoxyfructosazine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 282-285.
|
[6] |
PEI Yusheng, CHEN Chen, NING Xiao, CAI Tong.
Establishment and application of the first batch of national standards for bacterial endotoxin for monocyte activation reaction tests
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1217-1220.
|
[7] |
ZHONG Yingying, WANG Zhao, ZUO Tiantian, LI Yaolei, LI Hailiang, MA Shuangcheng.
Research progress on detection and risk assessment of exogenous heavy metals and related elements in Codonopsis Radix
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1309-1315.
|
[8] |
XIONG Jing, LIU Yi, LIU Zhaoxia, LI Jie, ZHANG Caiyu, WU Xiangxiang, HE Lan.
Development of the first national reference substance of ritonavir as a candidate drug against COVID-19
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 137-141.
|
[9] |
WANG Meng, ZHI Yajing, QIE Lanxia, GUO Jiahui, CAI Yuluo, NIU Liying.
Yi medicine Micromeria biflora (Buch.Ham.ex D.Don)Benth. standard decoction
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1315-1320.
|
[10] |
SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu.
A comparative progress and prospect for drug technological guidances system in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049.
|
[11] |
WANG Yue, SONG Yujuan, LIU Qian, ZHAO Xiangmei, DENG Lijuan, FAN Huihong.
Quality evaluation and quality research of domestic hydroxyethyl starch 130/0.4 injection
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1067-1072.
|
[12] |
XIONG Jing, YAN Jing, LIU Yi, LIU Yang, HE Lan.
Development of the first national reference substance of favipiravir as a candidate drug against COVID-19
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 52-56.
|
[13] |
ZHANG Xiaowen, LIU Jianping.
Introduction and Application of Standardization of case Reports on Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 459-463.
|
[14] |
ZHANG Wen, PENG Jing, CHEN Ju, LIU Jun, YANG Chunyan, WANG Peipei, YANG Xiaojun, YANG Kui, LIU Xiaoyun, ZHANG Haoran, ZHONG Zhengling, ZHAO Jun, TANG Zenghui, LUAN Jiajie.
Rational Use of Key Monitored Drugs Influenced by a Comprehensive Evaluation System for Clinical Medicine Based on Multidisciplinary Collaboration
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1166-1170.
|
[15] |
ZHANG Shiqing, ZHANG Xingdong.
Role of Standards in Medical Device Evaluation
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 1-3.
|